Tolerability data favour thiopurines over methotrexate

Trouble with the tolerability of conventional immunomodulators results in relatively high discontinuation rates despite their ongoing utility in the biologic era, Australian research shows. A retrospective study of 782 IBD patients on immunomodulators at two tertiary hospitals in Victoria has found discontinuation of methotrexate (40%) occurred at twice the rate as that of dose-optimised thiopurines ...

Already a member?

Login to keep reading.

© 2021 the limbic